Vilon vs Crystagen — Peptide Comparison

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Vilon

5–10 mg

Crystagen

1–100 mcg/kg

Frequency

Once daily

Administration

Subcutaneous injection

Cycle Length

12+ weeks

8-12 weeks

Onset Speed

Gradual (3-4 weeks)

Evidence Level

Limited human trials

Efficacy

Benefitratings

Immune System Revival

Healthy Aging

Digestive Support

Immune Rejuvenation

Cancer Defense

Technical Data

Compoundspecifications

Molecular Formula

C11H21N3O5

Molecular Weight

275.3 g/mol

Half-Life

Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic modifications to SIRT1/PARP gene expression; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1) when administered orally (demonstrated in animal studies); rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short dipeptide structure

CAS Number

45234-02-4

C14H21N3O8

359.3 g/mol

Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids

Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure

Not assigned (patented as immunogeroprotective peptide, US8057810B2)

Protocols

Dosingtiers

starting

200–500 mcg

5–10 day course

Common Khavinson-style introductory protocol for the KE (Lys-Glu) immune bioregulator; courses repeated 2–3 times yearly [6]. Research use only — no approved product.

standard

500 mcg

10–12 day course

Typical full-course practice dose; cycle repeated every 3–6 months [6].

advanced

Intramuscular delivery is also documented for the injectable KE bioregulator; same per-course dosing as subcutaneous [6].

200-400 mcg

10-20 days per course, repeated every 4-6 months

For the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]

Can also be given as an intramuscular injection at a similar dose, used in research practice. [6]

1-2 capsules (10 mg each)

1-2 times daily with meals

10-30 day course, repeated every 4-6 months

The oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. [6]

Applications

Bestsuited for

Immune system restoration in aging individuals with declining thymic function

Vilon is particularly well-suited for individuals focused on immune system restoration in aging individuals with declining thymic function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Adjunctive immunomodulatory support during cancer treatment protocols

Vilon is particularly well-suited for individuals focused on adjunctive immunomodulatory support during cancer treatment protocols. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity

Vilon is particularly well-suited for individuals focused on geroprotective therapy targeting sirt1/parp pathways for cellular longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols for anti-aging and immune support

Vilon is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for anti-aging and immune support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Restoring thymic function and immune competence in aging individuals with immune senescence

Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols for immune and anti-aging support

Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting immune function during and after illness recovery

Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Injection site reaction

Mild fatigue

Mild headache

Digestive changes

Uncommon

Flu-like symptoms

Serious

No documented serious adverse effects

Minor digestive changes

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature. Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk. Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity.

Contraindications

xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid)

xPregnancy and breastfeeding — insufficient reproductive safety data

xActive autoimmune disease in flare without medical supervision

xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.

xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)

xActive autoimmune disease in flare without physician supervision

Decision Guide

Which isright for you?

Choose Vilon if...

Immune system restoration in aging individuals with declining thymic function

Adjunctive immunomodulatory support during cancer treatment protocols

Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity

Comprehensive Khavinson bioregulator protocols for anti-aging and immune support

Choose Crystagen if...

Restoring thymic function and immune competence in aging individuals with immune senescence

Comprehensive Khavinson bioregulator protocols for immune and anti-aging support

Supporting immune function during and after illness recovery

Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Key takeaways

Melatonin is an endogenous hormone (232.28 g/mol indoleamine) acting through MT1/MT2 receptor pathways to regulate circadian rhythms, while Pinealon is a synthetic tripeptide (389 g/mol, Glu-Asp-Arg) that modulates gene expression in neural tissue through DNA interaction.
Melatonin's half-life of 20–50 minutes requires repeated dosing for sustained effect, whereas Pinealon's gene expression changes persist for weeks after a 10–20 day administration cycle.
Research applications do not overlap: melatonin addresses sleep-wake cycle disruption and acute oxidative stress, while Pinealon targets age-related neurodegeneration and cellular senescence through telomerase activation and BDNF upregulation.
Typical melatonin research doses range from 0.3–10mg oral/sublingual with effects measurable within 30–90 minutes, while Pinealon protocols use 10mg IM/SC daily for 10–20 days with outcome assessment over months.
The melatonin vs Pinealon comparison is fundamentally a choice between acute hormone receptor modulation (melatonin) and long-term epigenetic neuroprotection (Pinealon). They cannot substitute for one another in experimental design.
Melatonin exhibits direct antioxidant activity independent of receptor binding, scavenging hydroxyl radicals with approximately twice the molar capacity of vitamin E, while Pinealon's antioxidant effects are secondary to gene expression changes rather than direct radical scavenging.

realpeptides.co

comparison

Abarelix vs Degarelix — Peptide Comparison

Abarelix vs Degarelix — Peptide Comparison Abarelix vs Degarelix — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glan…

Source: peptideinitiative.comOpen reference →

comparison

Fertirelin vs Gonadorelin (GnRH) — Peptide Comparison

Fertirelin vs Gonadorelin (GnRH) — Peptide Comparison Fertirelin vs Gonadorelin (GnRH) — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is ri…

Source: peptideinitiative.comOpen reference →

comparison

Vesilute vs Prostamax — Peptide Comparison

Vesilute vs Prostamax — Peptide Comparison Vesilute vs Prostamax — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glan…

Source: peptideinitiative.comOpen reference →

Research context

Read sources and limitations before applying a claim.

Safety& evidence

FDA Status Research compound Safety Overview Cerluten is a peptide extract from cerebral tissue of young animals that is not FDA-approved and lacks rigorous clinical safety data. As an undefined mixture of peptides and proteins from animal sources, quality control and batch consistency cannot be guaranteed. Potential risks include allergic reactions to animal-derived proteins, contamination with microbial pathogens or prions, and unknown long-term immunological effects. No comprehensive safety studies have been conducted in humans, and the active pharmaceutical components have never been identified or standardized. The product exists primarily in Russian and Eastern European medical markets without Western regulatory oversight. Contraindications xKnown hypersensitivity to peptide bioregulators or bovine-derived products xPregnancy and breastfeeding — insufficient reproductive safety data xActive CNS infection — treat infection before initiating peptide bioregulator therapy xPrion disease concerns — although manufacturing processes include purification to remove proteins > 5 kDa, individuals with heightened prion risk should exercise caution Cortexin is a porcine brain-derived polypeptide preparation used in Russian neurology that is not FDA-approved and has no Western rigorous safety data. As an undefined mixture of peptides and proteins extracted from animal brains, batch standardization and quality control are not guaranteed. Concerns include potential transmissible spongiform encephalopathy (TSE/prion) risk from animal CNS tissue, although documented cases have not been reported. Allergic reactions to porcine proteins are possible. No formal human safety assessments, toxicology studies, or clinical trials by modern regulatory standards have been conducted. Use in Western countries is essentially non-existent due to regulatory limitations on animal-derived neurological products. xKnown hypersensitivity to Cortexin or any component including glycine stabilizer xAllergy to bovine-derived biological products xPregnancy — insufficient safety data for use during pregnancy xBreastfeeding — insufficient data on excretion into breast milk Decision Guide

Source: peptideinitiative.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Quickcomparison

Benefitratings

Compoundspecifications

Dosingtiers

Bestsuited for

Sideeffects

Safety& evidence

Which isright for you?

Abarelix vs Degarelix — Peptide Comparison

Fertirelin vs Gonadorelin (GnRH) — Peptide Comparison

Vesilute vs Prostamax — Peptide Comparison

Safety& evidence

Peptide Therapy Guide Editorial Team

Chonluten vs Crystagen — Peptide Comparison

VIP (Vasoactive Intestinal Peptide) vs PACAP-38 — Peptide Comparison

Vesilute vs Prostamax — Peptide Comparison

Triptorelin vs Leuprolide — Peptide Comparison